Rocket Pharmaceuticals Stock Surges 17% Premarket on FDA Alignment for Danon Disease Treatment
Tiger Newspress2023-09-13
Shares of Rocket Pharmaceuticals surged 17.59% to $17.98 in premarket trading on Wednesday after the company said it reached alignment with the Food and Drug Administration regarding its Phase 2 trial for the treatment of Danon disease.
The Cranbury, N.J.-based pharmaceutical company said its study would evaluate the use of the investigational gene therapy RP-A501 to treat 12 patients with Danon disease.
Danon is a rare genetic disorder that has no cure, and is known for weakening the heart and movement muscles, as well as intellectual disability.
The trial will support accelerated approval of Rocket's treatment by the FDA.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
